Quizartinib: Interim Phase II data

An ongoing, open-label, international Phase II trial in 53 evaluable patients showed that once-daily oral AC220 produced a CRc rate of 45% within the

Read the full 246 word article

How to gain access

Continue reading with a
two-week free trial.